Drug General Information (ID: DDIJPH7D52)
Drug Name			Ibritumomab tiuxetan		Drug Info		Streptokinase		Drug Info
Drug Type		Monoclonal antibody				Protein/peptide
Therapeutic Class		Antineoplastics				Thrombolytics

Mechanism of Ibritumomab tiuxetan-Streptokinase Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Streptokinase
Mechanism		Risk of bleeding Antiplatelet effects				Risk of bleeding Thrombolytic agent
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ibritumomab tiuxetan and Streptokinase

Recommended Action
Management		Caution is advised if ibritumomab is used in combination with drugs that interfere with platelet function or coagulation. Close clinical and laboratory observation for bleeding complications is recommended during and after ibritumomab therapy.

References
1	Product Information. In-111 Zevalin (ibritumomab). IDEC Pharmaceuticals Corporation, San Diego, CA.